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Background: Enzyme replacement therapy (ERT) in adults with Pompe disease, a progressive neuromuscular
disorder, is of promising but variable efficacy. We investigated whether it alters the course of disease, and also
identified potential prognostic factors.
Methods: Patients in this open-label single-center study were treated biweekly with 20 mg/kg alglucosidase alfa.
Muscle strength, muscle function, and pulmonary function were assessed every 3–6 months and analyzed using
repeated-measures ANOVA.
Results: Sixty-nine patients (median age 52.1 years) were followed for a median of 23 months. Muscle strength
increased after start of ERT (manual muscle testing 1.4 percentage points per year (pp/y); hand-held dynamometry
4.0 pp/y; both p < 0.001). Forced vital capacity (FVC) remained stable when measured in upright, but declined in
supine position (−1.1 pp/y; p = 0.03). Muscle function did not improve in all patients (quick motor function test
0.7 pp/y; p = 0.14), but increased significantly in wheelchair-independent patients and those with mild and
moderate muscle weakness.
Relative to the pre-treatment period (49 patients with 14 months pre-ERT and 22 months ERT median follow-up),
ERT affected muscle strength positively (manual muscle testing +3.3 pp/y, p < 0.001 and hand-held dynamometry
+7.9 pp/y, p < 0.001). Its effect on upright FVC was +1.8 pp/y (p = 0.08) and on supine FVC +0.8 (p = 0.38).
Favorable prognostic factors were female gender for muscle strength, and younger age and better clinical status for
supine FVC.
Conclusions: We conclude that ERT positively alters the natural course of Pompe disease in adult patients; muscle
strength increased and upright FVC stabilized. Functional outcome is probably best when ERT intervention is timely.
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Pompe disease (OMIM number 232300) is an autosomal
recessive metabolic myopathy caused by deficiency of
the lysosomal enzyme acid α-glucosidase. This deficiency
impairs lysosomal glycogen breakdown, leading to glyco-
gen accumulation in several tissues [1-4]. The disease
covers a broad clinical spectrum, ranging from a rapidly
progressive infantile phenotype that results in death
within the first year of life, to more slowly progressive
forms in children and adults [5-11]. In adults, the dis-
ease generally presents as a limb-girdle myopathy. As
well as the skeletal muscles, respiratory muscles – in-
cluding the diaphragm – are affected [1,12,13]. As the
disease progresses, most patients lose ambulation and
require ventilatory support [5,10,11,14,15].
Although Pompe disease used to be untreatable,
patients’ prospects changed in 2006 upon the introduc-
tion of enzyme replacement therapy (ERT) with recom-
binant human acid α-glucosidase. Initial studies in
infants showed that ERT improved survival and motor
outcome [16-23]. Several studies focusing on adult
patients have been published since registration, but most
report data in relatively small numbers of patients, or
have a short follow-up [24-29]. Proof of efficacy was pro-
vided by the 18-month randomized-placebo controlled
trial in 90 patients, 60 of whom received alglucosidase
alfa. This showed that walking distance improved and
pulmonary function in upright position stabilized [29].
As mild and severely affected patients had been
excluded, the trial involved a selected group of patients.
The aims of the current study were therefore 1) to de-
termine whether ERT alters the progressive course of
Pompe disease in a broader adult patient population
ranging from very severely affected to mildly affected; 2)
to determine how much ERT alters the course of the dis-
ease relative to that reflected in pre-treatment data; and
3) to identify prognostic factors for response to
treatment.
Methods
Patients and study design
This single-center, prospective, open-label cohort study
on the use of ERT was conducted from January 2005 to
August 2009 at the Center for Lysosomal and Metabolic
Diseases, Erasmus MC University Medical Center, Rot-
terdam, which is the Dutch national referral center for
Pompe patients.
Patients were eligible for inclusion if 1) they were over
18 years of age; 2) their diagnosis had been confirmed by
enzyme analysis in leukocytes or fibroblasts [30-32] and
by mutation analysis; [33] 3) they had not previously
been treated with recombinant human acid α-
glucosidase; 4) they had been treated for a minimum of
5 months; and 5) they were symptomatic, i.e. hadmeasurable muscle weakness and/or diminished pul-
monary function.
Patients received intravenous infusions with 20 mg/kg
alglucosidase alfa every two weeks. Clinical assessments
were performed every three to six months before the
start of ERT and every three months thereafter.
The study protocol was approved by the Medical Eth-
ical Committee at Erasmus MC University Medical Cen-
ter. All patients provided written informed consent.
Twenty of the 69 patients participated in the
randomized-placebo controlled trial on the safety and ef-
ficacy of alglucosidase alfa in late-onset Pompe disease;
13 in the treatment arm and seven in the placebo arm
[29]. Data on FVC in upright position of these patients
collected during the 18 months study period were
included in the current analyses.
Skeletal muscle strength and function
Skeletal muscle strength was measured by manual
muscle testing using the Medical Research Council
(MRC) grading scale (range 0–5) and hand-held dyna-
mometry (HHD) (Cytec dynamometer, Groningen, the
Netherlands) [34,35]. The following muscle groups were
tested: neck extensors, neck flexors, shoulder abductors,
elbow flexors, elbow extensors, hip flexors, hip abduc-
tors, knee flexors, and knee extensors. The MRC grade
was also assessed for shoulder adductors, exorotators
and endorotators, hip extensors, and hip adductors. An
MRC sumscore was derived by adding the grades for all
26 muscles and expressing the sum as a percentage of
the maximum possible score. HHD values (Newton) of
each muscle group were first expressed as a percentage
of the median strength of healthy males or females, [34]
and then combined into a sumscore by averaging these
for all 16 muscle groups. If values for three or more
muscle groups were missing, no sumscores were calcu-
lated for either method.
Muscle function was assessed using the Quick Motor
Function Test (QMFT); [36] this consists of 16 motor
skills related to daily activities that require the use of
muscles of the shoulder girdle, trunk, pelvic girdle and/
or proximal lower limbs. Each item was scored on a
5-point ordinal scale, with 0 representing ‘cannot per-
form task’ and 4 ‘can perform task with no effort’. Adding
all items gives a total score between 0 and 64. The actual
sumscore was expressed as a percentage of the maximum
score.
The use of wheelchair and walking aids was registered
at each visit.
Pulmonary function
Forced vital capacity (FVC) in upright and supine posi-
tions was measured using spirometry as described earlier
[13,37]. Results were expressed as a percentage of the
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of predicted normal values were considered to be abnor-
mal. The use of ventilatory support and hours of use per
day was registered at each visit.
Safety assessments and laboratory investigations
Vital signs and adverse events were recorded at each
visit. Electrocardiograms, a physical examination, and
hematological, biochemical and urine analyses were
made at regular intervals.
Statistical analysis
Longitudinal analysis of the outcome parameters (MRC,
HHD and QMFT sumscores and FVC in upright and su-
pine positions) was performed using repeated-measures
ANOVA (random coefficient models). This method
allows for irregular measurement times and different
treatment durations. First, we assessed the mean annual
change in the outcome parameters during the treatment
period. Mean annual changes were expressed in absolute
percentage points (pp/y). Analyses were also stratified by
subgroups described in previous studies: gender, age
(<45 years and ≥45 years old), disease duration (<15 years
and ≥15 years), wheelchair use, ventilation use, FVC in
upright position (≥80% and <80%) and MRC sumscore
(in tertiles) [13,29].
Second, for the patients with pre-treatment and treat-
ment data we established the extent to which the course
of disease altered after starting ERT. To be included in
this analysis, patients should have had at least one meas-
urement done a minimum of 4 months before ERT. We
included a linear effect of time before and during ERT in
the repeated-measures ANOVA. Per individual, the two
linear segments connect with each other at the time of
start of ERT. This method is also known as the “broken
stick method” or as “piece-wise linear regression”.
Third, we investigated prognostic factors for treatment
response. As well as performing the subgroup analysis,
we assessed the association between patients’ character-
istics and their individual response to ERT. Patients were
classified into three groups: 1) non-responders, i.e.
people in whom the course of disease (measured by one
of the outcome parameters) was the same or worse dur-
ing ERT than before; 2) good responders, whose disease
course improved more than the median improvement of
responders; and 3) moderate responders. Each patient’s
response was represented by the individual change in re-
gression lines calculated in the “broken stick” analysis.
In patients without pre-treatment data, the natural
course slope was imputed. Associations were tested
using the Spearman test for continuous variables and
the chi-square trend test for categorical variables.
Analyses were performed with SPSS for Windows (ver-
sion 17, SPSS Inc., Chicago, IL) or SAS (version 9.2, SASInstitute Inc., Cary, NC). A p-value lower than or equal
to 0.05 (two-sided) was considered significant.
Results
Patients
In total, 71 adult Pompe patients started ERT within the
study period. Two were excluded because they had
received ERT for less than five months: one died two
months after starting ERT due to a dissection of the aor-
tic arch; the second withdrew from the study after four
months and died six months later due to respiratory
insufficiency.
Table 1 shows the patients’ characteristics at start of
ERT. The median age at the start of ERT was 52.1 years,
52% were male, 40% used a wheelchair, and 37% used
mechanical ventilation. The median treatment duration
was 23 months (range 5 – 47 months). Of the 69
patients, 13 were treated for more than 3 years and six
patients for less than 1 year, respectively for 5, 6, 7, 10,
and two for 11 months.
All but one patient carried the common c.-32-13 T >
G (IVS1-13 T > G) mutation on one allele in combin-
ation with another pathogenic mutation on the second
allele. Of the patients carrying the c.-32-13 T > G (IVS1-
13 T > G) mutation, 14 different mutations were found
on the second allele. Forty-eight percent carried the
c.525 delT and 16% the c.2481 + 102-2646 + 31del muta-
tion. The other mutations found were the c.-32-13 T >
G+ c.1076-22 T > G, c.1115A > T, c.1396 G > T,
c.1548 G > A, c.172C > T, c.1799 G > A, c.2314 T > C,
c.378_379del, c.461_469del, c.701C > A, c.896 T > C and
c.925 G > A mutation. Of those mutations, 74% was indi-
cated as very severe and 26% as potentially less severe
(www.pompecenter.nl). For three patients the result of the
mutation analysis could not be tracked, because these
were performed by another center.
For 49 patients, pre-treatment data were available in
addition to the treatment follow-up. These were slightly
younger and less severely affected. Their median follow-
up was 14 months before (range 4–33), and 22 months
during ERT (range 6–41).Skeletal muscle strength
During ERT, the MRC sumscore among all 69 patients
rose by an average of 1.4 pp/y, and the HHD sumscore
by 4.0 pp/y (both p < 0.001; Table 2). All individual
muscle groups contributed to the effect (p ≤ 0.02 for all
muscle groups). Subgroup analyses showed that the
mean annual increase in muscle strength during ERT
was greater for women than for men (2.6 pp/y vs.
0.4 pp/y; difference between groups p < 0.001 for MRC;
and 6.3 pp/y vs. 2.0 pp/y, difference between groups p =
0.05 for HHD). For the other subgroups investigated,
Table 1 Patients’ characteristics and baseline values of clinical outcome measures at start of ERT
Characteristic Total study population
(N = 69)
Patients with pre-ERT and
ERT follow-up (N = 49)
P-value*
Age at start of ERT in years – median (range) 52.1 (26.2 – 76.3) 50.1 (26.2 – 74.0) 0.83
Age at onset of symptoms in years – median (range) 30.8 (1.4 – 62.0) 32.0 (1.4 – 62.0) 0.63
Age at diagnosis in years – median (range) 39.6 (1.4 – 63.8) 40.9 (1.4 – 63.0) 0.97
Duration of disease at start of ERT in years – median (range) 9.3 (0.2 – 31.2) 8.3 (0.5 – 31.2) 0.74
MRC sumscore at start of ERT in percentage – median (range) 77.7 (48.3 – 92.3) 79.2 (60.8 – 92.3) 0.52
HHD sumscore at start of ERT in percentage – median (range) 69.3 (25.9 – 94.1) 69.3 (25.9 – 94.1) 0.97
QMFT score at start of ERT in percentage – median (range) 55.6 (10.0 – 89.1) 59.5 (21.7 – 89.1) 0.42
Time of mechanical ventilation at start of ERT per day in hours – median (range) 11.5 (0.0 –24.0) 10.5 (0.0 –24.0) 0.81
FVC in upright position at start of ERT in percentage – median (range) 68.3 (11.3 – 106.9) 71.9 (26.5 – 106.9) 0.43
FVC in supine position at start of ERT in percentage – median (range) 46.8 (23.0 – 99.0) 52.4 (23.0 – 99.0) 0.71
Gender – No. of patients (%) 0.43
- Male 36 (52) 21 (43)
- Female 33 (48) 28 (57)
Wheelchair at start of ERT – No. of patients (%)
- No wheelchair use 42 (61) 33 (67) 0.22
- Partial wheelchair use 8 (12) 8 (16)
- Permanent wheelchair use 19 (28) 8 (16)
Mechanical ventilation at start of ERT – No. of patients (%)
- No mechanical ventilation 44 (64) 36 (74) 0.72
- Non-invasive mechanical ventilation 19 (28) 10 (20)
- Invasive mechanical ventilation 6 (9) 3 (6)
ERT = Enzyme Replacement Therapy; MRC sumscore = Medical Research Council sumscore; HHD sumscore = Hand-Held Dynamometry sumscore; QMFT score =
Quick Motor Function Test score; FVC = Forced Vital Capacity; N/No. = Number of patients.
* Differences between the total group (N = 69) and the group with pre-ERT and ERT follow-up (N = 49) were calculated using chi-square tests for the categorical
variables, and using Mann–Whitney tests for continuous variables.
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muscle strength during ERT.
Before the 49 patients with pre-treatment and treat-
ment data started ERT, their muscle-strength sumscores
declined significantly (−1.2 pp/y for MRC, p = 0.006;
–2.8 pp/y for HHD, p < 0.001). Treatment data produced
a significant improvement, the differences being +3.3 pp/
y for the MRC sumscore and +7.9 pp/y for the HHD
sumscore (both p < 0.001; Table 2, Figure 1A and B).Skeletal muscle function
Although QMFT scores for all 69 patients increased by
an average of 0.7 pp/y during ERT, this was not signifi-
cant (p = 0.14). Subgroup analyses showed that while
muscle function improved in patients with mild muscle
weakness (2.1 pp/y, p = 0.01) and moderate muscle
weakness (1.6 pp/y, p = 0.05), it fell by 1.4 pp/y (p =
0.08) in patients with severe muscle weakness (difference
between groups p = 0.004). In line with this, QMFT
scores rose in wheelchair-independent patients (1.7 pp/y,
p = 0.008), but did not improve in those who werewheelchair-dependent (−0.6 pp/y, p = 0.39; difference
between groups p = 0.02).
The number of patients who were partially or fully
wheelchair dependent at the last follow-up visit was the
same as at the start of ERT. Nevertheless, two of the 27
patients who used walking aids at the start of ERT
regained the ability to walk independently during ERT.
Two other patients became dependent on walking aids.
Pulmonary function and use of mechanical ventilation
During treatment with ERT, FVC in upright position
remained stable (0.1 pp/y, p = 0.92), while FVC in su-
pine position declined (−1.1, p = 0.03) (Table 2). Sub-
group analyses showed that FVC in supine position did
remain stable in patients under 45 years old (0.0 pp/y,
p = 1.0), but declined in those 45 years and over (−2.1 pp/y,
p = 0.002) (difference between groups p = 0.03). There
were no differences between subgroups for FVC in upright
position.
Before start of ERT, FVC in upright and supine posi-
tions both declined significantly (−2.0 pp/y, p = 0.001
and −1.8 pp/y, p = 0.002, respectively). Compared to
Table 2 Clinical outcome measures during enzyme replacement therapy and relative to the natural course of disease
Clinical Outcome Measure Natural course
mean pp/y (95% CI)
P-value
Treatment course
mean pp/y (95% CI)
P-value
Difference*
mean pp/y (95% CI)
P- value
MRC sumscore
Total study population (N = 69, M = 558)
1.4 (0.8 to 2.1) <0.001
MRC sumscore
Patients with pre-ERT + ERT follow-up (N = 49, M = 523)
−1.2 (−2.1 to −0.4) 0.006 2.1 (1.2 to 3.0) <0.001 3.3 (1.9 to 4.7) <0.001
HHD sumscore
Total study population (N = 64, M = 503)
4.0 (2.5 to 5.6) <0.001
HHD sumscore
Patients with pre-ERT + ERT follow-up (N = 42, M = 435)
−2.8 (−4.2 to −1.3) <0.001 5.1 (3.0 to 7.3) <0.001 7.9 (5.0 to 10.7) <0.001
QMFT score
Total study population (N = 69, M = 553)
0.7 (−0.2 to 1.7) 0.14
FVC in upright position
Total study population (N = 62, M = 475)
0.1 (−1.0 to 1.1) 0.92
FVC in upright position
Patients with pre-ERT + ERT follow-up (N = 46, M = 480)
−2.0 (−3.1 to −0.8) 0.001 −0.2 (−1.6 to 1.2) 0.76 1.8 (−0.2 to 3.7) 0.08
FVC in supine position
Total study population (N = 54, M = 411)
−1.1 (−2.1 to −0.1) 0.03
FVC in supine position
Patients with pre-ERT + ERT follow-up (N = 42, M = 436)
−1.8 (−2.9 to −0.7) 0.002 −1.0 (−2.3 to 0.3) 0.12 0.8 (−0.9 to 2.4) 0.38
ERT = Enzyme Replacement Therapy; pp/y = percentage points per year; 95% CI = 95% Confidence Interval; MRC sumscore = Medical Research Council sumscore;
QMFT score = Quick Motor Function Test score; HHD sumscore = Hand-Held Dynamometry sumscore; FVC = Forced Vital Capacity; N = Number of patients; M =
Number of Measurements. Data shown are mean changes in percentage points per year as calculated by repeated-measures ANOVA.
* Difference between the course of disease during treatment and the natural course.
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beit at borderline statistical significance (+1.8 pp/y, p =
0.08), while FVC in supine position did not (+0.8, p =
0.38) (Table 2 and Figure 1C and D).
For the whole group there was no change in the me-
dian number of hours of ventilation per day between the
start of ERT and the last treatment visit (Wilcoxon
signed-rank test p = 0.88). Mechanical ventilation time
could be reduced by one or more hours per day in nine
of the 25 patients who had been using mechanical venti-
lation at start of ERT. One of these was able to discon-
tinue the use of his ventilator. In 14 patients, ventilation
times remained the same, while ventilation was intensi-
fied in two. Nocturnal ventilation was initiated in two
others.
Individual response with regard to skeletal muscle
strength and pulmonary function
With regard to MRC sumscore, 31 patients (45%) were
good responders, 32 (46%) moderate, and six (9%) non-
responders (Figure 2). More women than men were
good responders (p = 0.002, Table 3). Twenty-seven of
the 62 patients with FVC data in upright position (44%)
responded well, 26 (42%) moderately, and nine (15%)
poorly. The characteristics between these FVC re-
sponder categories did not differ significantly.
Although FVC in supine position declined in the
whole group during ERT, almost two-thirds of patients
improved after starting ERT: 16 of 54 patients (30%)responded well, 17 (31%) moderately and 21 (39%) did
not respond (Figure 2). Better responses were associated
with younger age (p = 0.007), less severe muscle weak-
ness (p = 0.02), wheelchair independence (p = 0.05) and
better pulmonary function in upright position (p = 0.02)
(Table 3). None of the good responders were dependent
on artificial ventilation.
Responses for muscle strength correlated poorly with
responses for FVC. The correlation between response
categories for FVC in upright and supine was moderate
(Spearman’s ρ = 0.56, p <0.001).
Safety assessments and laboratory investigations
Laboratory safety parameters and ECGs remained un-
changed during ERT. In total, 12 patients (17%) devel-
oped one or more infusion-associated reaction (IARs).
These were similar to the IARs described in the
randomized-placebo controlled study; most could be
controlled by slowing infusion rates and/or giving pre-
medication [29]. To prevent further IARs, seven patients
received antihistamines as pre-medication, and five a
combination of antihistamines and corticosteroids. At
the end of the study three patients still had IARs, three
patients were using antihistamines as premedication and
two a combination of corticosteroids and antihistamines.
Enzyme replacement therapy was discontinued in three
patients who experienced IARs. In only one patient this
was for safety reasons: this patient had a medical history
of multiple auto-immune diseases and drug-induced
Figure 2 Individual response groups for skeletal muscle strength and pulmonary function. The number and percentage of good
responders, moderate responders and non-responders are shown for MRC sumscore, and forced vital capacity (FVC) in upright and supine positions.
Figure 1 The clinical course of disease before and after the start of enzyme replacement therapy (ERT) in the 49 patients with ERT and
pre-ERT follow-up data for A) MRC sumscore; B) hand-held dynamometry (HHD) sumscore; C) forced vital capacity (FVC) in upright
position; and D) FVC in supine position. The figure shows all the individual observations for the different outcome measures (shown as dots)
and the solid lines represent the estimated mean trend in these observations as calculated by the ‘broken stick’ repeated-measures ANOVA. The
dotted lines represent the extrapolated natural course slopes.
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Table 3 Characteristics of individual response groups with regard to skeletal muscle strength and pulmonary function
Non-responders Moderate Responders Good responders P-value
Response groups for MRC sumscore – No. of patients (%) 6 (9) 32 (46) 31 (45)
Female – No. of patients (%) 1 (17) 11 (34) 21 (68) 0.002
Age at start of ERT in years – median (range) 51.6 (38.0 – 66.2) 50.0 (26.2 – 67.0) 52.7 (29.2 – 76.3) 0.47
Disease duration at start of ERT in years – median (range) 12.1 (3.6 – 22.7) 11.1 (0.9 – 31.2) 9.0 (0.2 – 29.1) 0.55
MRC sumscore at start of ERT in percentage – median (range) 80.8 (60.8 – 86.9) 80.0 (48.3 – 91.5) 74.6 (53.3 – 92.3) 0.12
Wheelchair use at start of ERT – No. of patients (%) 2 (33) 9 (28) 16 (52) 0.11
FVC in upright position at start of ERT in percentage – median (range) 61.5 (34.4 – 79.3) 69.9 (11.3 – 105.0) 69.3 (16.4 – 106.9) 0.48
Ventilation use at start of ERT – No. of patients (%) 1 (17) 12 (38) 12 (39) 0.49
Response groups for FVC in upright position – No. of patients (%) 9 (15) 26 (42) 27 (44)
Female – No. of patients (%) 5 (56%) 14 (54%) 13 (48%) 0.64
Age at start of ERT in years – median (range) 52.6 (31.9 – 69.2) 51.2 (35.7 – 71.7) 43.3 (26.2 – 76.3) 0.16
Disease duration at start of ERT in years – median (range) 8.3 (0.6 – 31.2) 14.1 (0.9 – 27.0) 4.7 (0.2 – 29.1) 0.06
MRC sumscore at start of ERT in percentage – median (range) 74.6 (63.1 – 91.5) 77.7 (48.3 – 90.0) 80.8 (67.5 – 92.3) 0.26
Wheelchair use at start of ERT – No. of patients (%) 4 (44%) 10 (38%) 6 (22%) 0.15
FVC in upright position at start of ERT in percentage – median (range) 66.6 (51.4 – 100.5) 68.3 (11.3 – 106.9) 69.9 (16.4 – 105.0) 0.95
Ventilation use at start of ERT – No. of patients (%) 2 (22) 8 (31) 8 (30) 0.76
Response groups for FVC in supine position – No. of patients (%) 21 (39) 17 (31) 16 (30)
Female – No. of patients (%) 10 (48) 10 (59) 10 (63) 0.36
Age at start of ERT in years – median (range) 51.7 (31.9 – 67.0) 47.9 (26.2 – 62.9) 40.4 (29.2 – 74.0) 0.007
Disease duration at start of ERT in years – median (range) 10.7 (0.6 – 31.2) 4.7 (0.5-21.0) 5.0 (0.9 – 29.1) 0.12
MRC sumscore at start of ERT in percentage – median (range) 76.9 (60.8 – 91.5) 80.8 (69.2 – 90.8) 81.9 (69.2 – 92.3) 0.02
Wheelchair use at start of ERT – No. of patients (%) 8 (38) 2 (12) 2 (13) 0.05
FVC in upright position at start of ERT in percentage – median (range) 66.6 (45.4 – 106.9) 65.7 (41.5 – 105.8) 81.0 (62.6 – 105.0) 0.02
Ventilation use at start of ERT – No. of patients (%) 4 (19) 6 (35) 0 (0) 0.01
ERT = Enzyme Replacement Therapy; MRC sumscore = Medical Research Council sumscore; FVC = Forced Vital Capacity; No. = Number of patients.
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occurred with a very high antibody titer and a poor
response to ERT, as described previously [40].
Two severely affected patients died. Their causes of
death (sepsis after severe decubitus and chronic respira-
tory insufficiency) were considered to be unrelated to
ERT.
Discussion
This study describes a large cohort of adult Pompe
patients receiving treatment with alglucosidase alfa. It
reflects a unique situation in which most patients were
also prospectively followed before starting therapy,
thereby extending median follow-up to 3 years
(14 months before starting ERT and 23 months after-
wards). We found that ERT significantly altered the nat-
ural course of disease in adult Pompe patients. Muscle
strength increased significantly after they started ERT,
and FVC in upright position stabilized. Even though, at
group level, FVC in supine position and muscle function
did not improve during ERT, there were improvements
in certain subgroups of patients.Like previous studies, we found that muscle strength
deteriorated significantly before the start of therapy
[10,11] However, the improvement in muscle strength
after the start of ERT was greater than that reported in
other studies [25-27,29,41]. There may be various rea-
sons for this. Our study was restricted to adult patients,
but included patients across the entire disease spectrum.
We tested more muscle groups, included more patients,
and followed a longer treatment period than other stud-
ies, thereby producing over 500 measurements in total.
One new finding of this study is that women benefit
more from ERT with respect to muscle strength than
males. At the same dosage of 20 mg/kg bodyweight, it is
possible that the relative dose of alglucosidase alfa
received per gram of muscle-fiber tissue is higher in
women than in men. Men generally have a higher lean
body mass than women, and thus a somewhat higher
muscle mass per kg [42]. As women also have smaller
muscle fibers than men, they have a higher ratio of
muscle-fiber surface to muscle-fiber volume. Conse-
quently, they may have relatively more mannose
6-phosphate surface receptors, which mediate the uptake
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underlie the greater benefit women derive from ERT in-
clude muscle-fiber types, activity patterns, and hormonal
influences.
Our study did not incorporate the six-minute walk
test, a measure of functional endurance used in other
studies [24,27,29]. Instead, we assessed motor skills
related to daily activities, using the QMFT, which was
recently validated for use in patients with Pompe disease
[36]. Although there was no change in muscle function
across the entire group, there were significant improve-
ments in wheelchair-independent patients and those
with less pronounced muscle weakness. This finding
indicates that timely intervention with ERT may be cru-
cial to improving muscle function. The same is sug-
gested by the results of the subgroup analysis in the trial
of late-onset patients [29].
The stabilization of FVC in upright position in our
patients was similar to that recorded in the trial and in
other studies; [24-27,29] the decline in FVC before ERT
was similar to that observed in the placebo arm of the
trial and natural course studies [10,11,13,29].
This is the first study to report on the effect of ERT
on the FVC in supine position. In the whole study popu-
lation, this measure continued to deteriorate despite
ERT, but individual results showed an improvement in
almost two-thirds of patients. Patients were more likely
to improve if they were younger, were independent of
artificial ventilation, had a better FVC in upright pos-
ition, and had less severe muscle weakness at the start of
treatment. Again, this suggests that starting ERT early in
the disease course may be beneficial.
Because ERT has been available since 2006, we per-
formed an open-label study rather than a clinical trial,
assessing the effect of ERT in all adult patients – from
mild to severely affected – for many of whom we had
also collected pre-treatment data prospectively. As this
is an observational study, we could not correct for re-
sidual confounding. The small sample size inherent to
rare disorders meant that we could not apply a full
multivariate model to identify prognostic factors.Conclusions
In summary, by improving muscle strength and stabiliz-
ing pulmonary function in upright position, treatment
with alglucosidase alfa positively altered the natural
course of Pompe disease in adults. As well as finding
that female gender is potentially a favorable prognostic
factor for the effect of ERT on muscle strength, we
found that younger age and better clinical status are fa-
vorable prognostic factors for pulmonary function. This
suggests that it is important to start treatment early in
the course of disease. Prognostic variables may help toidentify patients with the best chances of benefiting from
treatment.
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